Olema Pharmaceuticals Holds Annual Stockholders Meeting

Olema Pharmaceuticals ( (OLMA) ) has issued an update.

On June 10, 2025, Olema Pharmaceuticals held its annual meeting of stockholders, where key decisions were made regarding the company’s governance and operations. Stockholders elected three Class II directors to serve until 2028, approved executive compensation, and ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for 2025. These decisions reflect the company’s ongoing commitment to strong leadership and financial oversight, which are crucial for its strategic goals and stakeholder confidence.

The most recent analyst rating on (OLMA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Olema Pharmaceuticals stock, see the OLMA Stock Forecast page.

Spark’s Take on OLMA Stock

According to Spark, TipRanks’ AI Analyst, OLMA is a Neutral.

Olema Pharmaceuticals faces substantial financial challenges with zero revenue and increasing losses, necessitating external funding. The technical analysis indicates some recent positive momentum, but the stock remains speculative due to negative profitability. The strategic collaboration with Novartis offers a positive outlook, potentially enhancing market position and supporting long-term growth. These factors collectively result in a moderate overall stock score.

To see Spark’s full report on OLMA stock, click here.

More about Olema Pharmaceuticals

Olema Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing targeted therapies for women’s cancers. The company is committed to advancing innovative treatments and improving outcomes for patients with cancer.

Average Trading Volume: 932,557

Technical Sentiment Signal: Sell

Current Market Cap: $279.2M

For an in-depth examination of OLMA stock, go to TipRanks’ Overview page.